ULTRAGRIS-165 Drug Patent Profile
When do Ultragris-165 patents expire, and what generic alternatives are available?
Ultragris-165 is a drug marketed by Pliva and is included in one NDA.
The generic ingredient in ULTRAGRIS-165 is griseofulvin, ultramicrocrystalline. There is one drug master file entry for this compound. Additional details are available on the griseofulvin, ultramicrocrystalline profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ULTRAGRIS-165?
- What are the global sales for ULTRAGRIS-165?
- What is Average Wholesale Price for ULTRAGRIS-165?
Summary for ULTRAGRIS-165
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 76 |
| Patent Applications: | 4,409 |
| DailyMed Link: | ULTRAGRIS-165 at DailyMed |
US Patents and Regulatory Information for ULTRAGRIS-165
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pliva | ULTRAGRIS-165 | griseofulvin, ultramicrocrystalline | TABLET;ORAL | 062645-001 | Jun 30, 1992 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
